City of Hope | Strategic Alliance Partners

March 14, 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

March 07, 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

March 07, 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

March 01, 2024

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

February 29, 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

February 29, 2024

Key safety considerations for the use of fruquintinib are explored.

February 23, 2024

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

February 23, 2024

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

February 22, 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

February 22, 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

February 19, 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

February 19, 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

February 16, 2024

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

February 16, 2024

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.

February 16, 2024

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

February 15, 2024

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

February 13, 2024

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

February 12, 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

February 12, 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

February 09, 2024

This session will focus on considerations and outcomes of allo-HSCT specifically among patients over 55 years of age. The panel will discuss how transplant protocols and supportive care measures can be optimized for this population who are at higher risk of comorbidities, toxicity and poor functional status.